Proteine di fusione ingegnerizzate
Pubblicazioni:
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties. Aaen KH, Testa MF, Nilsen J, Tarantino R, Canepari C, Benedusi M, Benjakul S, Nyquist-Andersen M, Herigstad ML, Cantore A, Valacchi G, Sandlie I, Bernardi F, Pinotti M, Branchini A, Andersen JT.
Nat Commun. 2025 Sep 29;16(1):8433.
doi: 10.1038/s41467-025-62955-9.
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity. Lombardi S, Aaen KH, Nilsen J, Ferrarese M, Gjølberg TT, Bernardi F, Pinotti M, Andersen JT, Branchini A.
Br J Haematol. 2021 Jul;194(2):453-462.
doi: 10.1111/bjh.17559.
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. Bern M, Nilsen J, Ferrarese M, Sand KMK, Gjølberg TT, Lode HE, Davidson RJ, Camire RM, Bækkevold ES, Foss S, Grevys A, Dalhus B, Wilson J, Høydahl LS, Christianson GJ, Roopenian DC, Schlothauer T, Michaelsen TE, Moe MC, Lombardi S, Pinotti M, Sandlie I, Branchini A, Andersen JT.
Sci Transl Med. 2020 Oct 14;12(565):eabb0580.
doi: 10.1126/scitranslmed.abb0580.
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies. Ferrarese M, Pignani S, Lombardi S, Balestra D, Bernardi F, Pinotti M, Branchini A.
Thromb Res. 2019 Jan;173:4-11
doi: 10.1016/j.thromres.2018.11.007